Figure S6


A
PCA (62.27%)
IL12-GEMy
No Treatment
PC2 (19.27%)
PC3 (15.55%)
PC1 (27.45%)
B
IL12-GEMy vs. No Treatment
Up-regulated
Down-regulated
Not significant
P-value
Fold change
Ciita
Arg1
Retnla
Il1b
Clca1
C
iCOS-iCOSL Signaling in T Helper Cells
PPAR Signaling
Th1 Pathway
IL-9 Signaling
Activation of IRF by Cytosolic PRRs
IL-17A Signaling in Airway Cells
Complement System
NFAT in Regulation of Immune Response
FLT3 Signaling in Hematopoietic Progenitor Cells
Interferon Signaling
Pattern Recognition Receptors
Dendritic Cell Maturation
Inflammasome pathway
TNFR2 Signaling
HMGB1 Signaling
Production of NO and ROS in Macrophages
mTOR Signaling
NRF2-mediated Oxidative Stress Response
iNOS Signaling
IL-8 Signaling
IL-6 Signaling
PI3K/AKT Signaling
CXCR4 Signaling
IL-1 Signaling
FcγR-mediated Phagocytosis
TGF-β Signaling
z-score
D
No Treatment
IL12-GEMy
UMAP_2
UMAP_1
Cytotoxic T Cells
Non−Cytotoxic T Cells
NK Cells
Dendritic Cells
Macrophages
Monocytes
Granulocytes
Other Lymphocytes
B Cells
MAST Cells
Non−Immune Stromal Cells
Endothelial Cells
Eosinophils
Epithelial Cells
Erythrocytes
E
Percent Survival
p = 0.0006
Day Post Tumor Inoculation
Tumor Volume (mm³)
IL12-GEMy
IL-12 Pre-Treated
Myeloid Control
No Treatment
Day 27 Primary Tumor
ns
No Treatment
Non-Transduced
IL-12 Pre-Treated
IL12-GEMy
F
Lung Metastasis
Avg Radiance (p/s/cm²/sr)
No/Low Metastasis
High Metastasis
Percent of Mice
G
Percent Survival
p = 0.0003
Day Post Tumor Inoculation
Tumor Volume (mm³)
No Treatment
High GEMy
Low GEMy
H
Subset T and NK cells
Recluster
UMAP_2
UMAP_1
Cytotoxic T Cells
Non−Cytotoxic T Cells
NK Cells
Dendritic Cells
Macrophages
Monocytes
Granulocytes
Other Lymphocytes
B Cells
MAST Cells
Non−Immune Stromal Cells
Endothelial Cells
Eosinophils
Epithelial Cells
Erythrocytes
CD8 - Dapl1
CD8 - Ccl5
CD8 - Ly6c2
CD8 - Hmgb2
CD4 - Igfbp4
CD4 Treg
Gamma Delta
NK - Ccl5
NK - Tyrobp
NK - AW112010
NK - Ccl4
Other